#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Functional	_
1-2	11-23	Connectivity	_
1-3	24-37	Abnormalities	_
1-4	38-41	and	_
1-5	42-52	Associated	_
1-6	53-62	Cognitive	_
1-7	63-71	Deficits	_
1-8	72-74	in	_
1-9	75-80	Fetal	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-10	81-88	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-11	89-97	Spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-12	98-107	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-13	108-109	(	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-14	110-114	FASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-15	115-116	)	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-16	117-127	Objectives	_
1-17	128-138	Consistent	_
1-18	139-143	with	_
1-19	144-159	well-documented	_
1-20	160-170	structural	_
1-21	171-174	and	_
1-22	175-190	microstructural	_
1-23	191-204	abnormalities	_
1-24	205-207	in	_
1-25	208-216	prenatal	http://maven.renci.org/NeuroBridge/neurobridge#AdrenalDisease
1-26	217-224	alcohol	_
1-27	225-233	exposure	_
1-28	234-235	(	_
1-29	236-239	PAE	_
1-30	240-241	)	_
1-31	242-243	,	_
1-32	244-250	recent	_
1-33	251-258	studies	_
1-34	259-266	suggest	_
1-35	267-271	that	_
1-36	272-282	functional	_
1-37	283-295	connectivity	_
1-38	296-297	(	_
1-39	298-300	FC	_
1-40	301-302	)	_
1-41	303-306	may	_
1-42	307-311	also	_
1-43	312-314	be	_
1-44	315-324	disrupted	_
1-45	325-326	.	_

2-1	327-329	We	_
2-2	330-339	evaluated	_
2-3	340-351	whole-brain	_
2-4	352-354	FC	_
2-5	355-357	in	_
2-6	358-359	a	_
2-7	360-365	large	_
2-8	366-376	multi-site	_
2-9	377-383	sample	_
2-10	384-385	,	_
2-11	386-394	examined	_
2-12	395-398	its	_
2-13	399-408	cognitive	_
2-14	409-419	correlates	_
2-15	420-421	,	_
2-16	422-425	and	_
2-17	426-434	explored	_
2-18	435-438	its	_
2-19	439-448	potential	_
2-20	449-451	to	_
2-21	452-463	objectively	_
2-22	464-472	identify	_
2-23	473-491	neurodevelopmental	_
2-24	492-503	abnormality	_
2-25	504-506	in	_
2-26	507-518	individuals	_
2-27	519-526	without	_
2-28	527-537	definitive	_
2-29	538-548	dysmorphic	_
2-30	549-557	features	_
2-31	558-559	.	_

3-1	560-572	Experimental	_
3-2	573-579	Design	_
3-3	580-588	Included	_
3-4	589-593	were	_
3-5	594-596	75	_
3-6	597-605	children	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
3-7	606-610	with	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
3-8	611-614	PAE	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
3-9	615-618	and	_
3-10	619-621	68	_
3-11	622-630	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-12	631-635	from	_
3-13	636-640	four	_
3-14	641-646	sites	_
3-15	647-648	.	_

4-1	649-652	All	_
4-2	653-665	participants	_
4-3	666-669	had	_
4-4	670-680	documented	_
4-5	681-686	heavy	_
4-6	687-695	prenatal	_
4-7	696-703	alcohol	_
4-8	704-712	exposure	_
4-9	713-714	.	_

5-1	715-718	All	_
5-2	719-728	underwent	_
5-3	729-730	a	_
5-4	731-737	formal	_
5-5	738-748	evaluation	_
5-6	749-751	of	_
5-7	752-760	physical	_
5-8	761-770	anomalies	_
5-9	771-774	and	_
5-10	775-785	dysmorphic	_
5-11	786-792	facial	_
5-12	793-801	features	_
5-13	802-803	.	_

6-1	804-807	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
6-2	808-812	data	_
6-3	813-817	were	_
6-4	818-827	collected	_
6-5	828-833	using	_
6-6	834-842	modified	_
6-7	843-850	matched	_
6-8	851-860	protocols	_
6-9	861-863	on	_
6-10	864-869	three	_
6-11	870-879	platforms	_
6-12	880-881	(	_
6-13	882-889	Siemens	_
6-14	890-891	,	_
6-15	892-894	GE	_
6-16	895-896	,	_
6-17	897-900	and	_
6-18	901-908	Philips	_
6-19	909-910	)	_
6-20	911-912	.	_

7-1	913-926	Resting-state	_
7-2	927-929	FC	_
7-3	930-933	was	_
7-4	934-942	examined	_
7-5	943-948	using	_
7-6	949-960	whole-brain	_
7-7	961-966	graph	_
7-8	967-973	theory	_
7-9	974-981	metrics	_
7-10	982-984	to	_
7-11	985-997	characterize	_
7-12	998-1002	each	_
7-13	1003-1013	individual	_
7-14	1014-1016	's	_
7-15	1017-1029	connectivity	_
7-16	1030-1031	.	_

8-1	1032-1041	Principal	_
8-2	1042-1054	Observations	_
8-3	1055-1063	Although	_
8-4	1064-1075	whole-brain	_
8-5	1076-1078	FC	_
8-6	1079-1086	metrics	_
8-7	1087-1090	did	_
8-8	1091-1094	not	_
8-9	1095-1107	discriminate	_
8-10	1108-1126	prenatally-exposed	_
8-11	1127-1131	from	_
8-12	1132-1141	unexposed	_
8-13	1142-1149	overall	_
8-14	1150-1151	,	_
8-15	1152-1160	atypical	_
8-16	1161-1163	FC	_
8-17	1164-1165	(	_
8-18	1166-1167	>	_
8-19	1168-1169	1	_
8-20	1170-1178	standard	_
8-21	1179-1188	deviation	_
8-22	1189-1193	from	_
8-23	1194-1197	the	_
8-24	1198-1203	grand	_
8-25	1204-1208	mean	_
8-26	1209-1210	)	_
8-27	1211-1214	was	_
8-28	1215-1228	significantly	_
8-29	1229-1233	more	_
8-30	1234-1240	common	_
8-31	1241-1242	(	_
8-32	1243-1246	2.7	_
8-33	1247-1252	times	_
8-34	1253-1254	)	_
8-35	1255-1257	in	_
8-36	1258-1261	the	_
8-37	1262-1265	PAE	_
8-38	1266-1271	group	_
8-39	1272-1275	vs.	_
8-40	1276-1284	controls	_
8-41	1285-1286	.	_

9-1	1287-1289	In	_
9-2	1290-1291	a	_
9-3	1292-1298	subset	_
9-4	1299-1301	of	_
9-5	1302-1304	55	_
9-6	1305-1316	individuals	_
9-7	1317-1318	(	_
9-8	1319-1322	PAE	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-9	1323-1326	and	_
9-10	1327-1335	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-11	1336-1337	)	_
9-12	1338-1343	whose	_
9-13	1344-1357	dysmorphology	_
9-14	1358-1369	examination	_
9-15	1370-1375	could	_
9-16	1376-1379	not	_
9-17	1380-1392	definitively	_
9-18	1393-1405	characterize	_
9-19	1406-1410	them	_
9-20	1411-1413	as	_
9-21	1414-1420	either	_
9-22	1421-1426	Fetal	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
9-23	1427-1434	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
9-24	1435-1443	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
9-25	1444-1445	(	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
9-26	1446-1449	FAS	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
9-27	1450-1451	)	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
9-28	1452-1454	or	_
9-29	1455-1462	non-FAS	_
9-30	1463-1464	,	_
9-31	1465-1473	atypical	_
9-32	1474-1476	FC	_
9-33	1477-1480	was	_
9-34	1481-1485	seen	_
9-35	1486-1488	in	_
9-36	1489-1491	27	_
9-37	1492-1493	%	_
9-38	1494-1496	of	_
9-39	1497-1500	the	_
9-40	1501-1504	PAE	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-41	1505-1510	group	_
9-42	1511-1512	,	_
9-43	1513-1516	but	_
9-44	1517-1518	0	_
9-45	1519-1520	%	_
9-46	1521-1523	of	_
9-47	1524-1532	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-48	1533-1534	.	_

10-1	1535-1541	Across	_
10-2	1542-1554	participants	_
10-3	1555-1556	,	_
10-4	1557-1558	a	_
10-5	1559-1560	1	_
10-6	1561-1562	%	_
10-7	1563-1573	difference	_
10-8	1574-1576	in	_
10-9	1577-1582	local	_
10-10	1583-1590	network	_
10-11	1591-1601	efficiency	_
10-12	1602-1605	was	_
10-13	1606-1616	associated	_
10-14	1617-1621	with	_
10-15	1622-1623	a	_
10-16	1624-1626	36	_
10-17	1627-1632	point	_
10-18	1633-1643	difference	_
10-19	1644-1646	in	_
10-20	1647-1653	global	_
10-21	1654-1663	cognitive	_
10-22	1664-1675	functioning	_
10-23	1676-1677	.	_

11-1	1678-1689	Conclusions	_
11-2	1690-1701	Whole-brain	_
11-3	1702-1704	FC	_
11-4	1705-1712	metrics	_
11-5	1713-1717	have	_
11-6	1718-1727	potential	_
11-7	1728-1730	to	_
11-8	1731-1739	identify	_
11-9	1740-1751	individuals	_
11-10	1752-1756	with	_
11-11	1757-1766	objective	_
11-12	1767-1785	neurodevelopmental	_
11-13	1786-1799	abnormalities	_
11-14	1800-1804	from	_
11-15	1805-1813	prenatal	_
11-16	1814-1821	alcohol	_
11-17	1822-1830	exposure	_
11-18	1831-1832	.	_

12-1	1833-1837	When	_
12-2	1838-1845	applied	_
12-3	1846-1848	to	_
12-4	1849-1860	individuals	_
12-5	1861-1867	unable	_
12-6	1868-1870	to	_
12-7	1871-1873	be	_
12-8	1874-1884	classified	_
12-9	1885-1887	as	_
12-10	1888-1891	FAS	http://maven.renci.org/NeuroBridge/neurobridge#FastingGlucose
12-11	1892-1894	or	_
12-12	1895-1902	non-FAS	_
12-13	1903-1907	from	_
12-14	1908-1921	dysmorphology	_
12-15	1922-1927	alone	_
12-16	1928-1929	,	_
12-17	1930-1935	these	_
12-18	1936-1944	measures	_
12-19	1945-1953	separate	_
12-20	1954-1972	prenatally-exposed	_
12-21	1973-1977	from	_
12-22	1978-1989	non-exposed	_
12-23	1990-1994	with	_
12-24	1995-1999	high	_
12-25	2000-2011	specificity	_
12-26	2012-2013	.	_

13-1	2014-2021	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
13-2	2022-2034	Participants	_
13-3	2035-2045	Background	_
13-4	2046-2057	information	_
13-5	2058-2063	about	_
13-6	2064-2067	the	_
13-7	2068-2074	CIFASD	_
13-8	2075-2082	project	_
13-9	2083-2085	is	_
13-10	2086-2095	available	_
13-11	2096-2098	in	_
13-12	2099-2100	a	_
13-13	2101-2109	separate	_
13-14	2110-2121	publication	_
13-15	2122-2125	and	_
13-16	2126-2128	at	_
13-17	2129-2143	www.cifasd.org	_
13-18	2144-2145	.	_

14-1	2146-2149	For	_
14-2	2150-2153	the	_
14-3	2154-2161	current	_
14-4	2162-2167	study	_
14-5	2168-2169	,	_
14-6	2170-2182	participants	_
14-7	2183-2187	were	_
14-8	2188-2197	recruited	_
14-9	2198-2202	from	_
14-10	2203-2207	four	_
14-11	2208-2214	CIFASD	_
14-12	2215-2220	sites	_
14-13	2221-2222	(	_
14-14	2223-2226	Los	_
14-15	2227-2234	Angeles	_
14-16	2235-2236	,	_
14-17	2237-2240	San	_
14-18	2241-2246	Diego	_
14-19	2247-2248	,	_
14-20	2249-2260	Minneapolis	_
14-21	2261-2262	,	_
14-22	2263-2270	Atlanta	_
14-23	2271-2272	)	_
14-24	2273-2280	between	_
14-25	2281-2285	2012	_
14-26	2286-2289	and	_
14-27	2290-2294	2014	_
14-28	2295-2296	.	_

15-1	2297-2305	Prenatal	_
15-2	2306-2313	alcohol	_
15-3	2314-2322	exposure	_
15-4	2323-2332	histories	_
15-5	2333-2337	were	_
15-6	2338-2346	obtained	_
15-7	2347-2354	through	_
15-8	2355-2368	retrospective	_
15-9	2369-2377	maternal	_
15-10	2378-2384	report	_
15-11	2385-2387	or	_
15-12	2388-2394	social	_
15-13	2395-2402	service	_
15-14	2403-2404	,	_
15-15	2405-2410	legal	_
15-16	2411-2412	,	_
15-17	2413-2415	or	_
15-18	2416-2423	medical	_
15-19	2424-2431	records	_
15-20	2432-2433	.	_

16-1	2434-2446	Participants	_
16-2	2447-2451	were	_
16-3	2452-2460	included	_
16-4	2461-2463	in	_
16-5	2464-2467	the	_
16-6	2468-2471	PAE	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
16-7	2472-2477	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
16-8	2478-2480	if	_
16-9	2481-2486	there	_
16-10	2487-2490	was	_
16-11	2491-2492	a	_
16-12	2493-2500	history	_
16-13	2501-2503	of	_
16-14	2504-2509	heavy	_
16-15	2510-2518	prenatal	_
16-16	2519-2526	alcohol	_
16-17	2527-2535	exposure	_
16-18	2536-2537	(	_
16-19	2538-2539	>	_
16-20	2540-2542	13	_
16-21	2543-2554	drinks/week	_
16-22	2555-2557	or	_
16-23	2558-2559	>	_
16-24	2560-2561	4	_
16-25	2562-2577	drinks/occasion	_
16-26	2578-2584	during	_
16-27	2585-2594	pregnancy	_
16-28	2595-2596	)	_
16-29	2597-2599	or	_
16-30	2600-2604	when	_
16-31	2605-2609	such	_
16-32	2610-2618	exposure	_
16-33	2619-2622	was	_
16-34	2623-2632	suspected	_
16-35	2633-2635	in	_
16-36	2636-2637	a	_
16-37	2638-2643	child	_
16-38	2644-2648	with	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
16-39	2649-2651	an	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
16-40	2652-2655	FAS	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
16-41	2656-2665	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
16-42	2666-2667	.	_

17-1	2668-2670	In	_
17-2	2671-2675	many	_
17-3	2676-2681	cases	_
17-4	2682-2683	,	_
17-5	2684-2692	detailed	_
17-6	2693-2700	history	_
17-7	2701-2706	about	_
17-8	2707-2715	exposure	_
17-9	2716-2723	amounts	_
17-10	2724-2726	or	_
17-11	2727-2735	patterns	_
17-12	2736-2738	of	_
17-13	2739-2747	exposure	_
17-14	2748-2751	was	_
17-15	2752-2764	unattainable	_
17-16	2765-2766	;	_
17-17	2767-2775	children	_
17-18	2776-2780	were	_
17-19	2781-2791	considered	_
17-20	2792-2794	to	_
17-21	2795-2799	have	_
17-22	2800-2805	heavy	_
17-23	2806-2814	prenatal	_
17-24	2815-2822	alcohol	_
17-25	2823-2831	exposure	_
17-26	2832-2834	if	_
17-27	2835-2842	mothers	_
17-28	2843-2847	were	_
17-29	2848-2853	known	_
17-30	2854-2856	to	_
17-31	2857-2859	be	_
17-32	2860-2861	“	_
17-33	2862-2871	alcoholic	_
17-34	2872-2873	”	_
17-35	2874-2876	or	_
17-36	2877-2892	alcohol-abusing	_
17-37	2893-2899	during	_
17-38	2900-2909	pregnancy	_
17-39	2910-2911	.	_

18-1	2912-2914	In	_
18-2	2915-2918	all	_
18-3	2919-2924	cases	_
18-4	2925-2926	,	_
18-5	2927-2934	alcohol	_
18-6	2935-2938	was	_
18-7	2939-2942	the	_
18-8	2943-2954	predominant	_
18-9	2955-2964	substance	_
18-10	2965-2967	of	_
18-11	2968-2973	abuse	_
18-12	2974-2975	.	_

19-1	2976-2988	Participants	_
19-2	2989-2993	were	_
19-3	2994-3002	included	_
19-4	3003-3005	in	_
19-5	3006-3009	the	_
19-6	3010-3021	non-exposed	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-7	3022-3029	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-8	3030-3035	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-9	3036-3038	if	_
19-10	3039-3044	there	_
19-11	3045-3048	was	_
19-12	3049-3050	a	_
19-13	3051-3059	reliable	_
19-14	3060-3067	history	_
19-15	3068-3070	of	_
19-16	3071-3075	only	_
19-17	3076-3083	minimal	_
19-18	3084-3085	(	_
19-19	3086-3087	<	_
19-20	3088-3089	1	_
19-21	3090-3100	drink/week	_
19-22	3101-3102	,	_
19-23	3103-3108	never	_
19-24	3109-3110	>	_
19-25	3111-3112	2	_
19-26	3113-3128	drinks/occasion	_
19-27	3129-3130	)	_
19-28	3131-3133	or	_
19-29	3134-3136	no	_
19-30	3137-3145	exposure	_
19-31	3146-3148	in	_
19-32	3149-3158	pregnancy	_
19-33	3159-3160	.	_

20-1	3161-3164	The	_
20-2	3165-3173	majority	_
20-3	3174-3176	of	_
20-4	3177-3189	participants	_
20-5	3190-3191	(	_
20-6	3192-3195	PAE	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-7	3196-3199	and	_
20-8	3200-3208	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
20-9	3209-3210	)	_
20-10	3211-3215	were	_
20-11	3216-3225	evaluated	_
20-12	3226-3231	using	_
20-13	3232-3233	a	_
20-14	3234-3246	standardized	_
20-15	3247-3260	dysmorphology	_
20-16	3261-3272	examination	_
20-17	3273-3282	conducted	_
20-18	3283-3285	by	_
20-19	3286-3289	the	_
20-20	3290-3296	CIFASD	_
20-21	3297-3310	Dysmorphology	_
20-22	3311-3315	Core	_
20-23	3316-3317	(	_
20-24	3318-3321	KLJ	_
20-25	3322-3323	)	_
20-26	3324-3325	.	_

21-1	3326-3331	Based	_
21-2	3332-3334	on	_
21-3	3335-3343	criteria	_
21-4	3344-3352	outlined	_
21-5	3353-3363	previously	_
21-6	3364-3365	,	_
21-7	3366-3369	the	_
21-8	3370-3380	evaluation	_
21-9	3381-3389	resulted	_
21-10	3390-3392	in	_
21-11	3393-3394	a	_
21-12	3395-3408	determination	_
21-13	3409-3411	of	_
21-14	3412-3413	1	_
21-15	3414-3415	)	_
21-16	3416-3421	Fetal	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
21-17	3422-3429	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
21-18	3430-3438	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
21-19	3439-3440	(	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
21-20	3441-3444	FAS	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
21-21	3445-3446	)	http://maven.renci.org/NeuroBridge/neurobridge#FetalAlcoholBehaviorScale
21-22	3447-3448	;	_
21-23	3449-3450	2	_
21-24	3451-3452	)	_
21-25	3453-3460	non-FAS	_
21-26	3461-3462	;	_
21-27	3463-3465	or	_
21-28	3466-3467	3	_
21-29	3468-3469	)	_
21-30	3470-3471	a	_
21-31	3472-3473	“	_
21-32	3474-3482	deferred	_
21-33	3483-3484	”	_
21-34	3485-3491	status	_
21-35	3492-3495	due	_
21-36	3496-3498	to	_
21-37	3499-3503	some	_
21-38	3504-3512	criteria	_
21-39	3513-3518	being	_
21-40	3519-3522	met	_
21-41	3523-3524	,	_
21-42	3525-3528	but	_
21-43	3529-3532	not	_
21-44	3533-3539	enough	_
21-45	3540-3542	to	_
21-46	3543-3551	diagnose	_
21-47	3552-3555	FAS	_
21-48	3556-3557	.	_

22-1	3558-3561	FAS	http://maven.renci.org/NeuroBridge/neurobridge#FastingGlucose
22-2	3562-3565	was	_
22-3	3566-3575	diagnosed	_
22-4	3576-3578	on	_
22-5	3579-3582	the	_
22-6	3583-3588	basis	_
22-7	3589-3591	of	_
22-8	3592-3595	two	_
22-9	3596-3598	or	_
22-10	3599-3603	more	_
22-11	3604-3606	of	_
22-12	3607-3610	the	_
22-13	3611-3620	following	_
22-14	3621-3624	key	_
22-15	3625-3631	facial	_
22-16	3632-3640	features	_
22-17	3641-3642	:	_
22-18	3643-3647	thin	_
22-19	3648-3658	vermillion	_
22-20	3659-3665	border	_
22-21	3666-3667	,	_
22-22	3668-3674	smooth	_
22-23	3675-3683	philtrum	_
22-24	3684-3685	,	_
22-25	3686-3689	and	_
22-26	3690-3695	short	_
22-27	3696-3705	palpebral	_
22-28	3706-3713	fissure	_
22-29	3714-3720	length	_
22-30	3721-3722	–	_
22-31	3723-3731	together	_
22-32	3732-3736	with	_
22-33	3737-3743	either	_
22-34	3744-3756	microcephaly	_
22-35	3757-3758	(	_
22-36	3759-3776	occipital-frontal	_
22-37	3777-3790	circumference	_
22-38	3791-3792	≤	_
22-39	3793-3795	10	_
22-40	3796-3797	%	_
22-41	3798-3799	)	_
22-42	3800-3802	or	_
22-43	3803-3809	growth	_
22-44	3810-3820	deficiency	_
22-45	3821-3822	(	_
22-46	3823-3829	height	_
22-47	3830-3832	or	_
22-48	3833-3839	weight	_
22-49	3840-3841	≤	_
22-50	3842-3844	10	_
22-51	3845-3846	%	_
22-52	3847-3848	)	_
22-53	3849-3851	or	_
22-54	3852-3856	both	_
22-55	3857-3858	.	_

23-1	3859-3862	The	_
23-2	3863-3871	deferred	_
23-3	3872-3878	status	_
23-4	3879-3882	was	_
23-5	3883-3890	applied	_
23-6	3891-3895	when	_
23-7	3896-3898	an	_
23-8	3899-3909	individual	_
23-9	3910-3913	had	_
23-10	3914-3915	A	_
23-11	3916-3917	.	_
23-12	3918-3919	)	_

24-1	3920-3923	One	_
24-2	3924-3927	key	_
24-3	3928-3938	dysmorphic	_
24-4	3939-3945	facial	_
24-5	3946-3953	feature	_
24-6	3954-3956	as	_
24-7	3957-3966	described	_
24-8	3967-3972	above	_
24-9	3973-3975	or	_
24-10	3976-3977	B	_
24-11	3978-3979	.	_
24-12	3980-3981	)	_

25-1	3982-3994	Microcephaly	_
25-2	3995-3998	and	_
25-3	3999-4005	growth	_
25-4	4006-4016	deficiency	_
25-5	4017-4018	,	_
25-6	4019-4021	or	_
25-7	4022-4024	C.	_
25-8	4025-4026	)	_
25-9	4027-4039	Microcephaly	_
25-10	4040-4042	or	_
25-11	4043-4049	growth	_
25-12	4050-4060	deficiency	_
25-13	4061-4064	and	_
25-14	4065-4068	one	_
25-15	4069-4079	additional	_
25-16	4080-4085	minor	_
25-17	4086-4096	non-facial	_
25-18	4097-4105	physical	_
25-19	4106-4118	malformation	_
25-20	4119-4120	(	_
25-21	4121-4129	railroad	_
25-22	4130-4135	track	_
25-23	4136-4139	ear	_
25-24	4140-4141	,	_
25-25	4142-4148	hockey	_
25-26	4149-4154	stick	_
25-27	4155-4161	palmar	_
25-28	4162-4168	crease	_
25-29	4169-4170	,	_
25-30	4171-4174	etc	_
25-31	4175-4176	.	_
25-32	4177-4178	)	_
25-33	4179-4180	.	_

26-1	4181-4182	A	_
26-2	4183-4194	significant	_
26-3	4195-4201	number	_
26-4	4202-4204	of	_
26-5	4205-4216	individuals	_
26-6	4217-4224	without	_
26-7	4225-4228	PAE	_
26-8	4229-4230	(	_
26-9	4231-4234	i.e	_
26-10	4235-4236	.	_

27-1	4237-4245	controls	_
27-2	4246-4247	)	_
27-3	4248-4256	received	_
27-4	4257-4258	a	_
27-5	4259-4260	“	_
27-6	4261-4269	deferred	_
27-7	4270-4271	”	_
27-8	4272-4286	classification	_
27-9	4287-4288	–	_
27-10	4289-4301	highlighting	_
27-11	4302-4305	the	_
27-12	4306-4310	fact	_
27-13	4311-4315	that	_
27-14	4316-4319	the	_
27-15	4320-4328	presence	_
27-16	4329-4331	of	_
27-17	4332-4335	one	_
27-18	4336-4346	dysmorphic	_
27-19	4347-4354	feature	_
27-20	4355-4357	is	_
27-21	4358-4368	relatively	_
27-22	4369-4375	common	_
27-23	4376-4379	and	_
27-24	4380-4383	not	_
27-25	4384-4394	diagnostic	_
27-26	4395-4397	in	_
27-27	4398-4401	and	_
27-28	4402-4404	of	_
27-29	4405-4411	itself	_
27-30	4412-4413	.	_

28-1	4414-4424	Additional	_
28-2	4425-4434	exclusion	_
28-3	4435-4443	criteria	_
28-4	4444-4447	for	_
28-5	4448-4451	all	_
28-6	4452-4460	subjects	_
28-7	4461-4465	were	_
28-8	4466-4473	another	_
28-9	4474-4487	developmental	_
28-10	4488-4496	disorder	_
28-11	4497-4498	(	_
28-12	4499-4501	ex	_
28-13	4502-4503	.	_

29-1	4504-4510	Autism	_
29-2	4511-4512	)	_
29-3	4513-4514	,	_
29-4	4515-4519	very	_
29-5	4520-4523	low	_
29-6	4524-4535	birthweight	_
29-7	4536-4537	(	_
29-8	4538-4539	<	_
29-9	4540-4544	1500	_
29-10	4545-4550	grams	_
29-11	4551-4552	)	_
29-12	4553-4554	,	_
29-13	4555-4564	traumatic	_
29-14	4565-4570	brain	_
29-15	4571-4577	injury	_
29-16	4578-4579	(	_
29-17	4580-4589	including	_
29-18	4590-4594	head	_
29-19	4595-4601	injury	_
29-20	4602-4606	with	_
29-21	4607-4611	loss	_
29-22	4612-4614	of	_
29-23	4615-4628	consciousness	_
29-24	4629-4630	>	_
29-25	4631-4633	30	_
29-26	4634-4641	minutes	_
29-27	4642-4643	)	_
29-28	4644-4645	,	_
29-29	4646-4651	other	_
29-30	4652-4659	medical	_
29-31	4660-4669	condition	_
29-32	4670-4679	affecting	_
29-33	4680-4683	the	_
29-34	4684-4689	brain	_
29-35	4690-4691	(	_
29-36	4692-4694	ex	_
29-37	4695-4696	.	_

30-1	4697-4705	Epilepsy	_
30-2	4706-4707	)	_
30-3	4708-4709	,	_
30-4	4710-4716	severe	_
30-5	4717-4728	psychiatric	_
30-6	4729-4739	disability	_
30-7	4740-4744	that	_
30-8	4745-4750	would	_
30-9	4751-4758	prevent	_
30-10	4759-4772	participation	_
30-11	4773-4774	(	_
30-12	4775-4777	ex	_
30-13	4778-4779	.	_

31-1	4780-4789	psychosis	_
31-2	4790-4792	or	_
31-3	4793-4798	mania	_
31-4	4799-4800	)	_
31-5	4801-4802	,	_
31-6	4803-4812	substance	_
31-7	4813-4816	use	_
31-8	4817-4819	by	_
31-9	4820-4823	the	_
31-10	4824-4835	participant	_
31-11	4836-4837	,	_
31-12	4838-4845	English	_
31-13	4846-4848	as	_
31-14	4849-4850	a	_
31-15	4851-4857	second	_
31-16	4858-4866	language	_
31-17	4867-4868	,	_
31-18	4869-4882	international	_
31-19	4883-4891	adoption	_
31-20	4892-4897	after	_
31-21	4898-4901	age	_
31-22	4902-4903	5	_
31-23	4904-4906	or	_
31-24	4907-4913	within	_
31-25	4914-4915	2	_
31-26	4916-4921	years	_
31-27	4922-4924	of	_
31-28	4925-4930	study	_
31-29	4931-4936	visit	_
31-30	4937-4938	,	_
31-31	4939-4941	or	_
31-32	4942-4959	contraindications	_
31-33	4960-4962	to	_
31-34	4963-4966	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-35	4967-4975	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-36	4976-4977	.	_

32-1	4978-4985	Control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
32-2	4986-4998	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
32-3	4999-5003	were	_
32-4	5004-5012	excluded	_
32-5	5013-5016	for	_
32-6	5017-5032	parent-reported	_
32-7	5033-5040	history	_
32-8	5041-5043	of	_
32-9	5044-5052	prenatal	_
32-10	5053-5062	substance	_
32-11	5063-5071	exposure	_
32-12	5072-5075	and	_
32-13	5076-5079	for	_
32-14	5080-5089	diagnosed	_
32-15	5090-5101	psychiatric	_
32-16	5102-5112	conditions	_
32-17	5113-5114	.	_

33-1	5115-5122	Parents	_
33-2	5123-5125	or	_
33-3	5126-5136	caregivers	_
33-4	5137-5139	of	_
33-5	5140-5143	all	_
33-6	5144-5156	participants	_
33-7	5157-5161	were	_
33-8	5162-5174	administered	_
33-9	5175-5178	the	_
33-10	5179-5189	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
33-11	5190-5199	Interview	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
33-12	5200-5208	Schedule	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
33-13	5209-5212	for	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
33-14	5213-5224	Children-IV	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
33-15	5225-5226	(	_
33-16	5227-5237	C-DISC-4.0	_
33-17	5238-5239	.	_

34-1	5240-5247	Because	_
34-2	5248-5261	pre-screening	_
34-3	5262-5265	was	_
34-4	5266-5274	utilized	_
34-5	5275-5281	during	_
34-6	5282-5293	recruitment	_
34-7	5294-5295	,	_
34-8	5296-5299	the	_
34-9	5300-5304	DISC	_
34-10	5305-5309	data	_
34-11	5310-5313	for	_
34-12	5314-5322	enrolled	_
34-13	5323-5335	participants	_
34-14	5336-5344	revealed	_
34-15	5345-5349	only	_
34-16	5350-5357	minimal	_
34-17	5358-5373	parent-reported	_
34-18	5374-5382	symptoms	_
34-19	5383-5385	in	_
34-20	5386-5389	the	_
34-21	5390-5397	control	_
34-22	5398-5403	group	_
34-23	5404-5405	(	_
34-24	5406-5407	2	_
34-25	5408-5416	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
34-26	5417-5420	had	_
34-27	5421-5425	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
34-28	5426-5434	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
34-29	5435-5436	,	_
34-30	5437-5438	5	_
34-31	5439-5442	had	_
34-32	5443-5455	Oppositional	_
34-33	5456-5463	Defiant	_
34-34	5464-5472	symptoms	_
34-35	5473-5474	,	_
34-36	5475-5478	and	_
34-37	5479-5480	3	_
34-38	5481-5484	had	_
34-39	5485-5492	Conduct	_
34-40	5493-5501	Disorder	_
34-41	5502-5510	symptoms	_
34-42	5511-5512	;	_
34-43	5513-5515	no	_
34-44	5516-5524	controls	_
34-45	5525-5528	had	_
34-46	5529-5536	anxiety	_
34-47	5537-5539	or	_
34-48	5540-5550	depressive	_
34-49	5551-5559	symptoms	_
34-50	5560-5562	or	_
34-51	5563-5568	other	_
34-52	5569-5574	major	_
34-53	5575-5586	psychiatric	_
34-54	5587-5595	symptoms	_
34-55	5596-5597	)	_
34-56	5598-5599	.	_

35-1	5600-5611	Psychiatric	_
35-2	5612-5624	co-morbidity	_
35-3	5625-5628	was	_
35-4	5629-5632	not	_
35-5	5633-5635	an	_
35-6	5636-5645	exclusion	_
35-7	5646-5655	criterion	_
35-8	5656-5659	for	_
35-9	5660-5672	participants	_
35-10	5673-5677	with	_
35-11	5678-5681	PAE	_
35-12	5682-5689	because	_
35-13	5690-5692	it	_
35-14	5693-5695	is	_
35-15	5696-5711	well-recognized	_
35-16	5712-5716	that	_
35-17	5717-5729	co-morbidity	_
35-18	5730-5732	is	_
35-19	5733-5737	high	_
35-20	5738-5740	in	_
35-21	5741-5745	FASD	http://maven.renci.org/NeuroBridge/neurobridge#FastingGlucose
35-22	5746-5747	.	_

36-1	5748-5753	Based	_
36-2	5754-5756	on	_
36-3	5757-5760	the	_
36-4	5761-5770	C-DISC-IV	_
36-5	5771-5775	data	_
36-6	5776-5777	,	_
36-7	5778-5780	54	_
36-8	5781-5793	participants	_
36-9	5794-5796	in	_
36-10	5797-5800	the	_
36-11	5801-5804	PAE	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
36-12	5805-5810	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
36-13	5811-5814	had	_
36-14	5815-5819	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
36-15	5820-5828	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
36-16	5829-5830	,	_
36-17	5831-5833	34	_
36-18	5834-5837	had	_
36-19	5838-5850	Oppositional	_
36-20	5851-5858	Defiant	_
36-21	5859-5867	symptoms	_
36-22	5868-5869	,	_
36-23	5870-5872	13	_
36-24	5873-5876	had	_
36-25	5877-5884	Conduct	_
36-26	5885-5893	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
36-27	5894-5902	symptoms	_
36-28	5903-5904	,	_
36-29	5905-5906	6	_
36-30	5907-5910	had	_
36-31	5911-5918	anxiety	_
36-32	5919-5927	disorder	_
36-33	5928-5936	symptoms	_
36-34	5937-5938	,	_
36-35	5939-5942	and	_
36-36	5943-5944	4	_
36-37	5945-5948	had	_
36-38	5949-5959	depressive	_
36-39	5960-5968	disorder	_
36-40	5969-5977	symptoms	_
36-41	5978-5979	.	_

37-1	5980-5992	Participants	_
37-2	5993-5997	were	_
37-3	5998-6002	7-17	_
37-4	6003-6007	year	_
37-5	6008-6011	old	_
37-6	6012-6014	at	_
37-7	6015-6018	the	_
37-8	6019-6023	time	_
37-9	6024-6026	of	_
37-10	6027-6041	neurocognitive	_
37-11	6042-6052	evaluation	_
37-12	6053-6056	and	_
37-13	6057-6060	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-14	6061-6069	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-15	6070-6071	.	_

38-1	6072-6075	The	_
38-2	6076-6080	vast	_
38-3	6081-6089	majority	_
38-4	6090-6092	of	_
38-5	6093-6105	participants	_
38-6	6106-6115	completed	_
38-7	6116-6119	the	_
38-8	6120-6134	neurocognitive	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveFunctionQuestionnaire
38-9	6135-6145	evaluation	_
38-10	6146-6149	and	_
38-11	6150-6153	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-12	6154-6156	on	_
38-13	6157-6160	the	_
38-14	6161-6165	same	_
38-15	6166-6169	day	_
38-16	6170-6171	.	_

39-1	6172-6174	In	_
39-2	6175-6176	a	_
39-3	6177-6180	few	_
39-4	6181-6186	cases	_
39-5	6187-6188	,	_
39-6	6189-6193	they	_
39-7	6194-6198	were	_
39-8	6199-6208	separated	_
39-9	6209-6211	by	_
39-10	6212-6213	a	_
39-11	6214-6217	few	_
39-12	6218-6222	days	_
39-13	6223-6225	or	_
39-14	6226-6231	weeks	_
39-15	6232-6233	.	_

40-1	6234-6235	A	_
40-2	6236-6241	total	_
40-3	6242-6244	of	_
40-4	6245-6248	165	_
40-5	6249-6261	participants	_
40-6	6262-6263	(	_
40-7	6264-6266	87	_
40-8	6267-6271	with	_
40-9	6272-6275	PAE	_
40-10	6276-6277	&	_
40-11	6278-6280	78	_
40-12	6281-6289	Controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
40-13	6290-6291	)	_
40-14	6292-6295	met	_
40-15	6296-6305	inclusion	_
40-16	6306-6314	criteria	_
40-17	6315-6316	.	_

41-1	6317-6322	Table	_
41-2	6323-6324	1	_
41-3	6325-6333	contains	_
41-4	6334-6337	the	_
41-5	6338-6350	demographics	_
41-6	6351-6354	for	_
41-7	6355-6358	the	_
41-8	6359-6371	participants	_
41-9	6372-6375	who	_
41-10	6376-6380	were	_
41-11	6381-6389	included	_
41-12	6390-6392	in	_
41-13	6393-6396	the	_
41-14	6397-6405	analyses	_
41-15	6406-6411	after	_
41-16	6412-6423	eliminating	_
41-17	6424-6429	those	_
41-18	6430-6434	with	_
41-19	6435-6444	excessive	_
41-20	6445-6453	movement	_
41-21	6454-6457	and	_
41-22	6458-6468	incomplete	_
41-23	6469-6477	networks	_
41-24	6478-6479	(	_
41-25	6480-6483	see	_
41-26	6484-6491	results	_
41-27	6492-6495	for	_
41-28	6496-6504	complete	_
41-29	6505-6516	description	_
41-30	6517-6518	)	_
41-31	6519-6520	.	_

42-1	6521-6524	All	_
42-2	6525-6537	participants	_
42-3	6538-6547	underwent	_
42-4	6548-6550	an	_
42-5	6551-6564	Institutional	_
42-6	6565-6571	Review	_
42-7	6572-6577	Board	_
42-8	6578-6579	(	_
42-9	6580-6583	IRB	_
42-10	6584-6585	)	_
42-11	6586-6595	-approved	_
42-12	6596-6604	informed	_
42-13	6605-6612	consent	_
42-14	6613-6620	process	_
42-15	6621-6630	involving	_
42-16	6631-6632	a	_
42-17	6633-6639	parent	_
42-18	6640-6642	or	_
42-19	6643-6651	guardian	_
42-20	6652-6654	as	_
42-21	6655-6659	well	_
42-22	6660-6662	as	_
42-23	6663-6664	a	_
42-24	6665-6673	separate	_
42-25	6674-6680	assent	_
42-26	6681-6688	process	_
42-27	6689-6693	with	_
42-28	6694-6697	the	_
42-29	6698-6703	child	_
42-30	6704-6705	.	_

43-1	6706-6709	All	_
43-2	6710-6715	study	_
43-3	6716-6726	procedures	_
43-4	6727-6731	were	_
43-5	6732-6740	approved	_
43-6	6741-6743	by	_
43-7	6744-6747	the	_
43-8	6748-6752	IRBs	_
43-9	6753-6755	at	_
43-10	6756-6760	each	_
43-11	6761-6763	of	_
43-12	6764-6767	the	_
43-13	6768-6772	four	_
43-14	6773-6778	sites	_
43-15	6779-6780	.	_

44-1	6781-6793	Participants	_
44-2	6794-6798	were	_
44-3	6799-6810	compensated	_
44-4	6811-6814	for	_
44-5	6815-6820	their	_
44-6	6821-6825	time	_
44-7	6826-6827	.	_

45-1	6828-6843	Neurobehavioral	_
45-2	6844-6854	Evaluation	_
45-3	6855-6862	Primary	_
45-4	6863-6873	caregivers	_
45-5	6874-6878	were	_
45-6	6879-6891	administered	_
45-7	6892-6900	specific	_
45-8	6901-6908	modules	_
45-9	6909-6913	from	_
45-10	6914-6917	the	_
45-11	6918-6926	C-DISC-4	_
45-12	6927-6928	,	_
45-13	6929-6930	a	_
45-14	6931-6943	computerized	_
45-15	6944-6954	structured	_
45-16	6955-6964	interview	_
45-17	6965-6970	based	_
45-18	6971-6973	on	_
45-19	6974-6977	the	_
45-20	6978-6984	DSM-IV	_
45-21	6985-6986	.	_

46-1	6987-7005	Neuropsychological	_
46-2	7006-7013	testing	_
46-3	7014-7017	was	_
46-4	7018-7027	conducted	_
46-5	7028-7034	during	_
46-6	7035-7038	one	_
46-7	7039-7041	or	_
46-8	7042-7045	two	_
46-9	7046-7054	sessions	_
46-10	7055-7057	by	_
46-11	7058-7065	trained	_
46-12	7066-7074	research	_
46-13	7075-7085	assistants	_
46-14	7086-7089	who	_
46-15	7090-7094	were	_
46-16	7095-7100	blind	_
46-17	7101-7103	to	_
46-18	7104-7112	exposure	_
46-19	7113-7119	status	_
46-20	7120-7121	.	_

47-1	7122-7129	Quality	_
47-2	7130-7137	control	_
47-3	7138-7145	methods	_
47-4	7146-7154	included	_
47-5	7155-7156	a	_
47-6	7157-7162	video	_
47-7	7163-7169	review	_
47-8	7170-7172	of	_
47-9	7173-7177	test	_
47-10	7178-7192	administration	_
47-11	7193-7203	procedures	_
47-12	7204-7207	and	_
47-13	7208-7209	a	_
47-14	7210-7217	scoring	_
47-15	7218-7223	check	_
47-16	7224-7227	for	_
47-17	7228-7233	every	_
47-18	7234-7238	10th	_
47-19	7239-7253	administration	_
47-20	7254-7255	.	_

48-1	7256-7260	From	_
48-2	7261-7262	a	_
48-3	7263-7269	larger	_
48-4	7270-7277	battery	_
48-5	7278-7280	of	_
48-6	7281-7299	neuropsychological	_
48-7	7300-7308	measures	_
48-8	7309-7321	administered	_
48-9	7322-7324	in	_
48-10	7325-7331	CIFASD	_
48-11	7332-7333	,	_
48-12	7334-7342	specific	_
48-13	7343-7351	measures	_
48-14	7352-7356	were	_
48-15	7357-7363	chosen	_
48-16	7364-7367	for	_
48-17	7368-7376	analyses	_
48-18	7377-7381	here	_
48-19	7382-7387	based	_
48-20	7388-7390	on	_
48-21	7391-7398	domains	_
48-22	7399-7403	that	_
48-23	7404-7410	showed	_
48-24	7411-7424	relationships	_
48-25	7425-7429	with	_
48-26	7430-7432	FC	_
48-27	7433-7435	in	_
48-28	7436-7444	previous	_
48-29	7445-7452	studies	_
48-30	7453-7454	.	_

49-1	7455-7460	These	_
49-2	7461-7468	include	_
49-3	7469-7472	the	_
49-4	7473-7485	Differential	http://maven.renci.org/NeuroBridge/neurobridge#UndifferentiatedSchizophrenia
49-5	7486-7493	Ability	http://maven.renci.org/NeuroBridge/neurobridge#UndifferentiatedSchizophrenia
49-6	7494-7500	Scales	http://maven.renci.org/NeuroBridge/neurobridge#UndifferentiatedSchizophrenia
49-7	7501-7502	–	http://maven.renci.org/NeuroBridge/neurobridge#UndifferentiatedSchizophrenia
49-8	7503-7509	Second	http://maven.renci.org/NeuroBridge/neurobridge#UndifferentiatedSchizophrenia
49-9	7510-7517	Edition	http://maven.renci.org/NeuroBridge/neurobridge#UndifferentiatedSchizophrenia
49-10	7518-7519	(	http://maven.renci.org/NeuroBridge/neurobridge#UndifferentiatedSchizophrenia
49-11	7520-7526	DAS-II	http://maven.renci.org/NeuroBridge/neurobridge#UndifferentiatedSchizophrenia
49-12	7527-7528	)	http://maven.renci.org/NeuroBridge/neurobridge#UndifferentiatedSchizophrenia
49-13	7529-7530	,	_
49-14	7531-7534	the	_
49-15	7535-7545	California	http://maven.renci.org/NeuroBridge/neurobridge#II
49-16	7546-7552	Verbal	http://maven.renci.org/NeuroBridge/neurobridge#II
49-17	7553-7561	Learning	http://maven.renci.org/NeuroBridge/neurobridge#II
49-18	7562-7566	Test	http://maven.renci.org/NeuroBridge/neurobridge#II
49-19	7567-7568	–	http://maven.renci.org/NeuroBridge/neurobridge#II
49-20	7569-7577	Children	http://maven.renci.org/NeuroBridge/neurobridge#II
49-21	7578-7580	's	_
49-22	7581-7588	Edition	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
49-23	7589-7590	(	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
49-24	7591-7597	CVLT-C	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
49-25	7598-7599	)	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
49-26	7600-7601	,	_
49-27	7602-7605	the	_
49-28	7606-7618	Delis-Kaplan	_
49-29	7619-7628	Executive	http://maven.renci.org/NeuroBridge/neurobridge#BehaviorRatingInventoryOfExecutiveFunction
49-30	7629-7640	Functioning	http://maven.renci.org/NeuroBridge/neurobridge#BehaviorRatingInventoryOfExecutiveFunction
49-31	7641-7647	System	http://maven.renci.org/NeuroBridge/neurobridge#BehaviorRatingInventoryOfExecutiveFunction
49-32	7648-7649	(	http://maven.renci.org/NeuroBridge/neurobridge#BehaviorRatingInventoryOfExecutiveFunction
49-33	7650-7656	D-KEFS	_
49-34	7657-7658	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
49-35	7659-7660	,	_
49-36	7661-7664	and	_
49-37	7665-7668	the	_
49-38	7669-7677	NEPSY-II	http://maven.renci.org/NeuroBridge/neurobridge#II
49-39	7678-7691	Developmental	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
49-40	7692-7710	Neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
49-41	7711-7721	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#DevelopmentalNeuropsychologicalAssessment
49-42	7722-7723	.	_

50-1	7724-7727	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
50-2	7728-7739	Acquisition	_
50-3	7740-7750	Procedures	_
50-4	7751-7754	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
50-5	7755-7759	data	_
50-6	7760-7764	were	_
50-7	7765-7773	acquired	_
50-8	7774-7776	at	_
50-9	7777-7781	four	_
50-10	7782-7787	sites	_
50-11	7788-7790	on	_
50-12	7791-7799	scanners	_
50-13	7800-7804	from	_
50-14	7805-7810	three	_
50-15	7811-7818	vendors	_
50-16	7819-7820	:	_
50-17	7821-7829	Children	_
50-18	7830-7832	's	_
50-19	7833-7841	Hospital	_
50-20	7842-7844	of	_
50-21	7845-7848	Los	_
50-22	7849-7856	Angeles	_
50-23	7857-7858	(	_
50-24	7859-7866	Philips	_
50-25	7867-7874	Achieva	_
50-26	7875-7876	)	_
50-27	7877-7878	;	_
50-28	7879-7889	University	_
50-29	7890-7892	of	_
50-30	7893-7903	California	_
50-31	7904-7905	–	_
50-32	7906-7909	San	_
50-33	7910-7915	Diego	_
50-34	7916-7917	(	_
50-35	7918-7925	General	_
50-36	7926-7934	Electric	_
50-37	7935-7940	MR750	_
50-38	7941-7942	)	_
50-39	7943-7944	;	_
50-40	7945-7955	University	_
50-41	7956-7958	of	_
50-42	7959-7968	Minnesota	_
50-43	7969-7972	and	_
50-44	7973-7978	Emory	_
50-45	7979-7989	University	_
50-46	7990-7991	(	_
50-47	7992-7996	both	_
50-48	7997-8004	Siemens	_
50-49	8005-8008	Tim	_
50-50	8009-8013	Trio	_
50-51	8014-8015	)	_
50-52	8016-8017	.	_

51-1	8018-8029	Acquisition	_
51-2	8030-8039	sequences	_
51-3	8040-8044	were	_
51-4	8045-8052	modeled	_
51-5	8053-8055	on	_
51-6	8056-8065	protocols	_
51-7	8066-8075	developed	_
51-8	8076-8079	for	_
51-9	8080-8090	multi-site	_
51-10	8091-8098	imaging	_
51-11	8099-8101	by	_
51-12	8102-8105	the	_
51-13	8106-8115	Pediatric	_
51-14	8116-8123	Imaging	_
51-15	8124-8138	Neurocognition	_
51-16	8139-8142	and	_
51-17	8143-8151	Genetics	_
51-18	8152-8153	(	_
51-19	8154-8158	PING	_
51-20	8159-8160	)	_
51-21	8161-8166	group	_
51-22	8167-8168	(	_
51-23	8169-8174	Table	_
51-24	8175-8176	2	_
51-25	8177-8178	)	_
51-26	8179-8180	(	_
51-27	8181-8185	http	_
51-28	8186-8187	:	_
51-29	8188-8207	//ping.chd.ucsd.edu	_
51-30	8208-8209	)	_
51-31	8210-8211	.	_

52-1	8212-8215	The	_
52-2	8216-8224	sequence	_
52-3	8225-8233	included	_
52-4	8234-8238	high	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
52-5	8239-8249	resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
52-6	8250-8261	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-7	8262-8268	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-8	8269-8270	,	_
52-9	8271-8272	a	_
52-10	8273-8284	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
52-11	8285-8288	set	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
52-12	8289-8290	,	_
52-13	8291-8303	30-direction	_
52-14	8304-8307	DTI	_
52-15	8308-8309	,	_
52-16	8310-8313	and	_
52-17	8314-8327	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
52-18	8328-8331	EPI	_
52-19	8332-8337	scans	_
52-20	8338-8341	for	_
52-21	8342-8355	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
52-22	8356-8360	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
52-23	8361-8362	.	_

53-1	8363-8366	The	_
53-2	8367-8378	acquisition	_
53-3	8379-8389	parameters	_
53-4	8390-8392	in	_
53-5	8393-8398	Table	_
53-6	8399-8400	2	_
53-7	8401-8404	are	_
53-8	8405-8409	just	_
53-9	8410-8415	those	_
53-10	8416-8419	for	_
53-11	8420-8424	data	_
53-12	8425-8433	examined	_
53-13	8434-8436	in	_
53-14	8437-8440	the	_
53-15	8441-8448	current	_
53-16	8449-8452	set	_
53-17	8453-8455	of	_
53-18	8456-8464	analyses	_
53-19	8465-8466	(	_
53-20	8467-8469	T1	_
53-21	8470-8473	and	_
53-22	8474-8478	fMRI	_
53-23	8479-8480	)	_
53-24	8481-8482	.	_

54-1	8483-8495	Participants	_
54-2	8496-8500	were	_
54-3	8501-8504	not	_
54-4	8505-8512	sedated	_
54-5	8513-8516	for	_
54-6	8517-8520	the	_
54-7	8521-8524	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
54-8	8525-8529	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
54-9	8530-8533	nor	_
54-10	8534-8538	were	_
54-11	8539-8544	their	_
54-12	8545-8550	usual	_
54-13	8551-8562	medications	_
54-14	8563-8571	modified	_
54-15	8572-8573	.	_

55-1	8574-8580	During	_
55-2	8581-8584	the	_
55-3	8585-8598	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
55-4	8599-8603	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
55-5	8604-8608	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
55-6	8609-8610	,	_
55-7	8611-8623	participants	_
55-8	8624-8628	were	_
55-9	8629-8639	instructed	_
55-10	8640-8642	to	_
55-11	8643-8648	close	_
55-12	8649-8654	their	_
55-13	8655-8659	eyes	_
55-14	8660-8663	and	_
55-15	8664-8670	remain	_
55-16	8671-8676	still	_
55-17	8677-8678	.	_

56-1	8679-8684	Table	_
56-2	8685-8686	2	_
56-3	8687-8695	contains	_
56-4	8696-8703	details	_
56-5	8704-8706	of	_
56-6	8707-8710	the	_
56-7	8711-8722	acquisition	_
56-8	8723-8732	sequences	_
56-9	8733-8735	by	_
56-10	8736-8740	site	_
56-11	8741-8742	.	_

57-1	8743-8746	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
57-2	8747-8757	Processing	_
57-3	8758-8760	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
57-4	8761-8769	Cortical	_
57-5	8770-8782	Parcellation	_
57-6	8783-8791	Cortical	_
57-7	8792-8804	parcellation	_
57-8	8805-8807	of	_
57-9	8808-8811	the	_
57-10	8812-8814	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
57-11	8815-8821	volume	_
57-12	8822-8825	was	_
57-13	8826-8835	performed	_
57-14	8836-8841	using	_
57-15	8842-8852	FreeSurfer	_
57-16	8853-8860	version	_
57-17	8861-8866	5.3.0	_
57-18	8867-8868	(	_
57-19	8869-8895	surfer.nmr.mgh.harvard.edu	_
57-20	8896-8897	)	_
57-21	8898-8901	and	_
57-22	8902-8905	the	_
57-23	8906-8913	default	_
57-24	8914-8930	Desikan-Killiany	_
57-25	8931-8936	atlas	_
57-26	8937-8938	.	_

58-1	8939-8949	Processing	_
58-2	8950-8958	included	_
58-3	8959-8966	removal	_
58-4	8967-8969	of	_
58-5	8970-8979	non-brain	_
58-6	8980-8986	tissue	_
58-7	8987-8988	,	_
58-8	8989-8998	automated	_
58-9	8999-9008	Talairach	_
58-10	9009-9023	transformation	_
58-11	9024-9025	,	_
58-12	9026-9038	segmentation	_
58-13	9039-9040	,	_
58-14	9041-9050	intensity	_
58-15	9051-9064	normalization	_
58-16	9065-9066	,	_
58-17	9067-9079	tessellation	_
58-18	9080-9082	of	_
58-19	9083-9086	the	_
58-20	9087-9091	grey	_
58-21	9092-9098	matter	_
58-22	9099-9100	/	_
58-23	9101-9106	white	_
58-24	9107-9113	matter	_
58-25	9114-9122	boundary	_
58-26	9123-9124	,	_
58-27	9125-9133	topology	_
58-28	9134-9144	correction	_
58-29	9145-9146	,	_
58-30	9147-9154	surface	_
58-31	9155-9166	deformation	_
58-32	9167-9168	,	_
58-33	9169-9172	and	_
58-34	9173-9182	automated	_
58-35	9183-9195	parcellation	_
58-36	9196-9198	of	_
58-37	9199-9202	the	_
58-38	9203-9211	cortical	_
58-39	9212-9216	grey	_
58-40	9217-9223	matter	_
58-41	9224-9228	into	_
58-42	9229-9231	34	_
58-43	9232-9236	ROIs	_
58-44	9237-9240	per	_
58-45	9241-9251	hemisphere	_
58-46	9252-9253	.	_

59-1	9254-9258	Each	_
59-2	9259-9266	subject	_
59-3	9267-9269	's	_
59-4	9270-9274	data	_
59-5	9275-9278	was	_
59-6	9279-9287	visually	_
59-7	9288-9297	inspected	_
59-8	9298-9300	by	_
59-9	9301-9302	a	_
59-10	9303-9310	trained	_
59-11	9311-9319	operator	_
59-12	9320-9322	to	_
59-13	9323-9329	ensure	_
59-14	9330-9338	accuracy	_
59-15	9339-9341	of	_
59-16	9342-9345	the	_
59-17	9346-9354	cortical	_
59-18	9355-9367	parcellation	_
59-19	9368-9369	,	_
59-20	9370-9373	but	_
59-21	9374-9380	manual	_
59-22	9381-9388	editing	_
59-23	9389-9392	was	_
59-24	9393-9396	not	_
59-25	9397-9405	employed	_
59-26	9406-9407	.	_

60-1	9408-9421	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
60-2	9422-9426	Fmri	_
60-3	9427-9437	Processing	_
60-4	9438-9442	FMRI	_
60-5	9443-9447	data	_
60-6	9448-9458	processing	_
60-7	9459-9462	was	_
60-8	9463-9470	carried	_
60-9	9471-9474	out	_
60-10	9475-9480	using	_
60-11	9481-9484	the	_
60-12	9485-9489	FEAT	_
60-13	9490-9494	tool	_
60-14	9495-9499	from	_
60-15	9500-9503	the	_
60-16	9504-9509	FMRIB	_
60-17	9510-9518	Software	_
60-18	9519-9526	Library	_
60-19	9527-9528	(	_
60-20	9529-9532	FSL	_
60-21	9533-9534	)	_
60-22	9535-9542	version	_
60-23	9543-9548	5.0.7	_
60-24	9549-9550	(	_
60-25	9551-9555	http	_
60-26	9556-9557	:	_
60-27	9558-9591	//fsl.fmrib.ox.ac.uk/fsl/fslwiki/	_
60-28	9592-9593	)	_
60-29	9594-9595	.	_

61-1	9596-9599	The	_
61-2	9600-9609	following	_
61-3	9610-9624	pre-statistics	_
61-4	9625-9635	processing	_
61-5	9636-9639	was	_
61-6	9640-9647	applied	_
61-7	9648-9649	:	_
61-8	9650-9656	motion	_
61-9	9657-9667	correction	_
61-10	9668-9669	,	_
61-11	9670-9675	brain	_
61-12	9676-9686	extraction	_
61-13	9687-9688	,	_
61-14	9689-9696	spatial	_
61-15	9697-9706	smoothing	_
61-16	9707-9708	(	_
61-17	9709-9712	6mm	_
61-18	9713-9717	FWHM	_
61-19	9718-9719	)	_
61-20	9720-9721	,	_
61-21	9722-9732	grand-mean	_
61-22	9733-9742	intensity	_
61-23	9743-9756	normalization	_
61-24	9757-9758	,	_
61-25	9759-9762	and	_
61-26	9763-9767	high	_
61-27	9768-9772	pass	_
61-28	9773-9781	temporal	_
61-29	9782-9791	filtering	_
61-30	9792-9793	(	_
61-31	9794-9803	sigma=50s	_
61-32	9804-9805	)	_
61-33	9806-9807	.	_

62-1	9808-9818	Correction	_
62-2	9819-9822	for	_
62-3	9823-9832	geometric	_
62-4	9833-9843	distortion	_
62-5	9844-9850	caused	_
62-6	9851-9853	by	_
62-7	9854-9862	magnetic	_
62-8	9863-9868	field	_
62-9	9869-9882	inhomogeneity	_
62-10	9883-9886	was	_
62-11	9887-9894	carried	_
62-12	9895-9898	out	_
62-13	9899-9901	on	_
62-14	9902-9903	a	_
62-15	9904-9910	subset	_
62-16	9911-9913	of	_
62-17	9914-9918	data	_
62-18	9919-9920	:	_
62-19	9921-9926	those	_
62-20	9927-9931	data	_
62-21	9932-9936	that	_
62-22	9937-9941	were	_
62-23	9942-9951	collected	_
62-24	9952-9957	along	_
62-25	9958-9962	with	_
62-26	9963-9964	a	_
62-27	9965-9972	reverse	_
62-28	9973-9986	phase-encoded	_
62-29	9987-9995	gradient	_
62-30	9996-10000	echo	_
62-31	10001-10005	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
62-32	10006-10010	scan	_
62-33	10011-10019	acquired	_
62-34	10020-10023	for	_
62-35	10024-10028	this	_
62-36	10029-10036	purpose	_
62-37	10037-10038	(	_
62-38	10039-10042	all	_
62-39	10043-10052	Minnesota	_
62-40	10053-10057	data	_
62-41	10058-10061	and	_
62-42	10062-10063	a	_
62-43	10064-10070	subset	_
62-44	10071-10073	of	_
62-45	10074-10077	the	_
62-46	10078-10085	Atlanta	_
62-47	10086-10090	data	_
62-48	10091-10092	)	_
62-49	10093-10094	.	_

63-1	10095-10104	ICA-based	_
63-2	10105-10109	data	_
63-3	10110-10118	analysis	_
63-4	10119-10122	was	_
63-5	10123-10127	also	_
63-6	10128-10135	carried	_
63-7	10136-10139	out	_
63-8	10140-10146	during	_
63-9	10147-10150	the	_
63-10	10151-10155	FEAT	_
63-11	10156-10166	processing	_
63-12	10167-10171	step	_
63-13	10172-10177	using	_
63-14	10178-10181	the	_
63-15	10182-10185	FSL	_
63-16	10186-10190	tool	_
63-17	10191-10198	MELODIC	_
63-18	10199-10200	.	_

64-1	10201-10204	The	_
64-2	10205-10208	FSL	_
64-3	10209-10213	tool	_
64-4	10214-10221	fsl_fix	_
64-5	10222-10225	was	_
64-6	10226-10230	then	_
64-7	10231-10235	used	_
64-8	10236-10238	to	_
64-9	10239-10246	perform	_
64-10	10247-10256	automated	_
64-11	10257-10260	ICA	_
64-12	10261-10271	de-noising	_
64-13	10272-10274	of	_
64-14	10275-10278	the	_
64-15	10279-10283	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
64-16	10284-10288	data	_
64-17	10289-10290	.	_

65-1	10291-10303	Registration	_
65-2	10304-10306	of	_
65-3	10307-10310	the	_
65-4	10311-10313	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
65-5	10314-10320	volume	_
65-6	10321-10323	to	_
65-7	10324-10327	the	_
65-8	10328-10332	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
65-9	10333-10337	data	_
65-10	10338-10341	was	_
65-11	10342-10351	performed	_
65-12	10352-10357	using	_
65-13	10358-10361	the	_
65-14	10362-10372	FreeSurfer	_
65-15	10373-10377	tool	_
65-16	10378-10388	bbregister	_
65-17	10389-10390	.	_

66-1	10391-10396	White	_
66-2	10397-10403	matter	_
66-3	10404-10407	and	_
66-4	10408-10411	CSF	_
66-5	10412-10417	masks	_
66-6	10418-10422	were	_
66-7	10423-10430	created	_
66-8	10431-10433	on	_
66-9	10434-10437	the	_
66-10	10438-10442	fMRI	_
66-11	10443-10447	data	_
66-12	10448-10450	by	_
66-13	10451-10462	registering	_
66-14	10463-10466	the	_
66-15	10467-10476	bilateral	_
66-16	10477-10487	FreeSurfer	_
66-17	10488-10495	lateral	_
66-18	10496-10505	ventricle	_
66-19	10506-10509	and	_
66-20	10510-10515	white	_
66-21	10516-10522	matter	_
66-22	10523-10527	ROIs	_
66-23	10528-10533	using	_
66-24	10534-10537	the	_
66-25	10538-10559	bbregister-determined	_
66-26	10560-10569	transform	_
66-27	10570-10577	applied	_
66-28	10578-10583	using	_
66-29	10584-10587	the	_
66-30	10588-10591	FSL	_
66-31	10592-10596	tool	_
66-32	10597-10602	FLIRT	_
66-33	10603-10604	.	_

67-1	10605-10616	Timecourses	_
67-2	10617-10621	from	_
67-3	10622-10625	the	_
67-4	10626-10629	CSF	_
67-5	10630-10633	and	_
67-6	10634-10639	white	_
67-7	10640-10646	matter	_
67-8	10647-10651	ROIs	_
67-9	10652-10657	along	_
67-10	10658-10662	with	_
67-11	10663-10666	the	_
67-12	10667-10670	six	_
67-13	10671-10677	motion	_
67-14	10678-10688	parameters	_
67-15	10689-10693	were	_
67-16	10694-10698	then	_
67-17	10699-10703	used	_
67-18	10704-10706	as	_
67-19	10707-10717	voxel-wise	_
67-20	10718-10726	nuisance	_
67-21	10727-10737	regressors	_
67-22	10738-10740	in	_
67-23	10741-10751	processing	_
67-24	10752-10755	the	_
67-25	10756-10760	fMRI	_
67-26	10761-10765	data	_
67-27	10766-10770	with	_
67-28	10771-10774	the	_
67-29	10775-10778	FSL	_
67-30	10779-10783	tool	_
67-31	10784-10792	film_gls	_
67-32	10793-10794	.	_

68-1	10795-10797	To	_
68-2	10798-10805	further	_
68-3	10806-10812	reduce	_
68-4	10813-10824	artifactual	_
68-5	10825-10837	correlations	_
68-6	10838-10844	within	_
68-7	10845-10848	the	_
68-8	10849-10853	fMRI	_
68-9	10854-10858	data	_
68-10	10859-10860	,	_
68-11	10861-10867	volume	_
68-12	10868-10877	scrubbing	_
68-13	10878-10881	was	_
68-14	10882-10889	applied	_
68-15	10890-10892	to	_
68-16	10893-10896	the	_
68-17	10897-10901	data	_
68-18	10902-10907	using	_
68-19	10908-10915	methods	_
68-20	10916-10924	outlined	_
68-21	10925-10927	in	_
68-22	10928-10929	.	_

69-1	10930-10941	Time-Series	_
69-2	10942-10952	Extraction	_
69-3	10953-10956	The	_
69-4	10957-10959	68	_
69-5	10960-10970	Freesurfer	_
69-6	10971-10979	cortical	_
69-7	10980-10984	ROIs	_
69-8	10985-10986	(	_
69-9	10987-10989	34	_
69-10	10990-10993	per	_
69-11	10994-11004	hemisphere	_
69-12	11005-11006	)	_
69-13	11007-11011	were	_
69-14	11012-11022	registered	_
69-15	11023-11025	to	_
69-16	11026-11029	the	_
69-17	11030-11039	processed	_
69-18	11040-11044	fMRI	_
69-19	11045-11049	data	_
69-20	11050-11055	using	_
69-21	11056-11066	bbregister	_
69-22	11067-11068	.	_

70-1	11069-11072	The	_
70-2	11073-11086	parcellations	_
70-3	11087-11091	were	_
70-4	11092-11099	dilated	_
70-5	11100-11106	during	_
70-6	11107-11119	registration	_
70-7	11120-11121	,	_
70-8	11122-11125	but	_
70-9	11126-11130	none	_
70-10	11131-11135	were	_
70-11	11136-11143	allowed	_
70-12	11144-11146	to	_
70-13	11147-11154	overlap	_
70-14	11155-11158	and	_
70-15	11159-11165	voxels	_
70-16	11166-11173	outside	_
70-17	11174-11177	the	_
70-18	11178-11188	brain-mask	_
70-19	11189-11193	were	_
70-20	11194-11202	excluded	_
70-21	11203-11204	.	_

71-1	11205-11209	ROIs	_
71-2	11210-11214	that	_
71-3	11215-11224	contained	_
71-4	11225-11230	fewer	_
71-5	11231-11235	than	_
71-6	11236-11238	10	_
71-7	11239-11243	fMRI	_
71-8	11244-11250	voxels	_
71-9	11251-11254	for	_
71-10	11255-11258	any	_
71-11	11259-11270	participant	_
71-12	11271-11275	were	_
71-13	11276-11284	excluded	_
71-14	11285-11289	from	_
71-15	11290-11293	the	_
71-16	11294-11299	final	_
71-17	11300-11308	analysis	_
71-18	11309-11310	.	_

72-1	11311-11315	This	_
72-2	11316-11324	resulted	_
72-3	11325-11327	in	_
72-4	11328-11331	the	_
72-5	11332-11341	exclusion	_
72-6	11342-11344	of	_
72-7	11345-11346	6	_
72-8	11347-11351	ROIs	_
72-9	11352-11353	(	_
72-10	11354-11363	bilateral	_
72-11	11364-11374	entorhinal	_
72-12	11375-11376	,	_
72-13	11377-11384	frontal	_
72-14	11385-11389	pole	_
72-15	11390-11393	and	_
72-16	11394-11402	temporal	_
72-17	11403-11407	pole	_
72-18	11408-11409	)	_
72-19	11410-11411	,	_
72-20	11412-11419	leaving	_
72-21	11420-11421	a	_
72-22	11422-11427	total	_
72-23	11428-11430	of	_
72-24	11431-11433	62	_
72-25	11434-11438	ROIs	_
72-26	11439-11440	(	_
72-27	11441-11443	31	_
72-28	11444-11447	per	_
72-29	11448-11458	hemisphere	_
72-30	11459-11460	)	_
72-31	11461-11462	.	_

73-1	11463-11466	The	_
73-2	11467-11471	mean	_
73-3	11472-11476	fMRI	_
73-4	11477-11488	time-series	_
73-5	11489-11491	of	_
73-6	11492-11495	all	_
73-7	11496-11502	voxels	_
73-8	11503-11509	within	_
73-9	11510-11514	each	_
73-10	11515-11518	ROI	_
73-11	11519-11523	were	_
73-12	11524-11528	then	_
73-13	11529-11538	extracted	_
73-14	11539-11542	for	_
73-15	11543-11547	each	_
73-16	11548-11559	participant	_
73-17	11560-11561	.	_

74-1	11562-11573	Computation	_
74-2	11574-11576	Of	_
74-3	11577-11580	The	_
74-4	11581-11588	Network	_
74-5	11589-11596	Metrics	_
74-6	11597-11604	Pearson	_
74-7	11605-11617	correlations	_
74-8	11618-11622	were	_
74-9	11623-11631	computed	_
74-10	11632-11639	between	_
74-11	11640-11643	the	_
74-12	11644-11655	time-series	_
74-13	11656-11660	from	_
74-14	11661-11664	all	_
74-15	11665-11673	possible	_
74-16	11674-11679	pairs	_
74-17	11680-11682	of	_
74-18	11683-11686	the	_
74-19	11687-11689	62	_
74-20	11690-11698	cortical	_
74-21	11699-11703	ROIs	_
74-22	11704-11709	using	_
74-23	11710-11716	MATLAB	_
74-24	11717-11718	(	_
74-25	11719-11728	Mathworks	_
74-26	11729-11730	,	_
74-27	11731-11737	Natick	_
74-28	11738-11739	,	_
74-29	11740-11742	MA	_
74-30	11743-11744	)	_
74-31	11745-11746	.	_

75-1	11747-11752	Graph	_
75-2	11753-11759	theory	_
75-3	11760-11767	network	_
75-4	11768-11775	metrics	_
75-5	11776-11780	were	_
75-6	11781-11789	computed	_
75-7	11790-11793	for	_
75-8	11794-11798	each	_
75-9	11799-11806	subject	_
75-10	11807-11809	's	_
75-11	11810-11817	Pearson	_
75-12	11818-11829	correlation	_
75-13	11830-11836	matrix	_
75-14	11837-11846	utilizing	_
75-15	11847-11852	tools	_
75-16	11853-11857	from	_
75-17	11858-11861	the	_
75-18	11862-11865	BCT	_
75-19	11866-11873	toolbox	_
75-20	11874-11875	(	_
75-21	11876-11880	http	_
75-22	11881-11882	:	_
75-23	11883-11943	//sites.google.com/a/brain-connectivity-toolbox.net/bct/Home	_
75-24	11944-11945	)	_
75-25	11946-11947	.	_

76-1	11948-11956	Cortical	_
76-2	11957-11961	ROIs	_
76-3	11962-11968	served	_
76-4	11969-11971	as	_
76-5	11972-11979	network	_
76-6	11980-11985	nodes	_
76-7	11986-11989	and	_
76-8	11990-12001	correlation	_
76-9	12002-12008	values	_
76-10	12009-12015	served	_
76-11	12016-12018	as	_
76-12	12019-12022	the	_
76-13	12023-12034	connections	_
76-14	12035-12036	(	_
76-15	12037-12042	edges	_
76-16	12043-12044	)	_
76-17	12045-12046	.	_

77-1	12047-12050	The	_
77-2	12051-12055	cost	_
77-3	12056-12058	of	_
77-4	12059-12060	a	_
77-5	12061-12068	network	_
77-6	12069-12071	is	_
77-7	12072-12079	defined	_
77-8	12080-12082	as	_
77-9	12083-12086	the	_
77-10	12087-12092	ratio	_
77-11	12093-12095	of	_
77-12	12096-12104	existing	_
77-13	12105-12116	connections	_
77-14	12117-12119	to	_
77-15	12120-12123	the	_
77-16	12124-12129	total	_
77-17	12130-12136	number	_
77-18	12137-12139	of	_
77-19	12140-12148	possible	_
77-20	12149-12160	connections	_
77-21	12161-12163	in	_
77-22	12164-12167	the	_
77-23	12168-12173	graph	_
77-24	12174-12175	(	_
77-25	12176-12177	(	_
77-26	12178-12180	62	_
77-27	12181-12182	*	_
77-28	12183-12185	61	_
77-29	12186-12187	)	_
77-30	12188-12189	/	_
77-31	12190-12191	2	_
77-32	12192-12193	=	_
77-33	12194-12198	1891	_
77-34	12199-12202	for	_
77-35	12203-12204	a	_
77-36	12205-12207	62	_
77-37	12208-12212	node	_
77-38	12213-12220	network	_
77-39	12221-12222	)	_
77-40	12223-12224	.	_

78-1	12225-12231	Binary	_
78-2	12232-12233	,	_
78-3	12234-12246	non-weighted	_
78-4	12247-12250	and	_
78-5	12251-12266	non-directional	_
78-6	12267-12276	adjacency	_
78-7	12277-12285	matrices	_
78-8	12286-12290	were	_
78-9	12291-12301	determined	_
78-10	12302-12304	by	_
78-11	12305-12313	applying	_
78-12	12314-12315	a	_
78-13	12316-12336	participant-specific	_
78-14	12337-12346	threshold	_
78-15	12347-12349	to	_
78-16	12350-12354	each	_
78-17	12355-12366	participant	_
78-18	12367-12369	's	_
78-19	12370-12374	data	_
78-20	12375-12381	across	_
78-21	12382-12383	a	_
78-22	12384-12389	range	_
78-23	12390-12392	of	_
78-24	12393-12398	costs	_
78-25	12399-12403	from	_
78-26	12404-12407	0.1	_
78-27	12408-12410	to	_
78-28	12411-12414	0.5	_
78-29	12415-12416	,	_
78-30	12417-12421	with	_
78-31	12422-12426	0.05	_
78-32	12427-12431	step	_
78-33	12432-12442	increments	_
78-34	12443-12444	.	_

79-1	12445-12449	Four	_
79-2	12450-12457	metrics	_
79-3	12458-12460	of	_
79-4	12461-12469	interest	_
79-5	12470-12474	were	_
79-6	12475-12482	derived	_
79-7	12483-12484	:	_
79-8	12485-12499	characteristic	_
79-9	12500-12504	path	_
79-10	12505-12511	length	_
79-11	12512-12513	,	_
79-12	12514-12518	mean	_
79-13	12519-12529	clustering	_
79-14	12530-12541	coefficient	_
79-15	12542-12543	,	_
79-16	12544-12549	local	_
79-17	12550-12560	efficiency	_
79-18	12561-12564	and	_
79-19	12565-12571	global	_
79-20	12572-12582	efficiency	_
79-21	12583-12584	.	_

80-1	12585-12589	Path	_
80-2	12590-12596	length	_
80-3	12597-12599	is	_
80-4	12600-12603	the	_
80-5	12604-12612	smallest	_
80-6	12613-12619	number	_
80-7	12620-12622	of	_
80-8	12623-12634	connections	_
80-9	12635-12639	that	_
80-10	12640-12644	must	_
80-11	12645-12647	be	_
80-12	12648-12657	traversed	_
80-13	12658-12660	to	_
80-14	12661-12668	connect	_
80-15	12669-12672	any	_
80-16	12673-12677	pair	_
80-17	12678-12680	of	_
80-18	12681-12686	nodes	_
80-19	12687-12689	in	_
80-20	12690-12693	the	_
80-21	12694-12701	network	_
80-22	12702-12703	.	_

81-1	12704-12707	The	_
81-2	12708-12722	characteristic	_
81-3	12723-12727	path	_
81-4	12728-12734	length	_
81-5	12735-12736	(	_
81-6	12737-12740	CPL	_
81-7	12741-12742	)	_
81-8	12743-12745	is	_
81-9	12746-12749	the	_
81-10	12750-12757	average	_
81-11	12758-12762	path	_
81-12	12763-12769	length	_
81-13	12770-12777	between	_
81-14	12778-12781	all	_
81-15	12782-12787	pairs	_
81-16	12788-12790	of	_
81-17	12791-12796	nodes	_
81-18	12797-12799	in	_
81-19	12800-12803	the	_
81-20	12804-12811	network	_
81-21	12812-12813	.	_

82-1	12814-12815	A	_
82-2	12816-12822	higher	_
82-3	12823-12827	than	_
82-4	12828-12834	normal	_
82-5	12835-12838	CPL	_
82-6	12839-12846	implies	_
82-7	12847-12851	less	_
82-8	12852-12860	reliance	_
82-9	12861-12863	on	_
82-10	12864-12870	highly	_
82-11	12871-12880	efficient	_
82-12	12881-12882	“	_
82-13	12883-12894	trunk-lines	_
82-14	12895-12896	”	_
82-15	12897-12900	for	_
82-16	12901-12905	long	_
82-17	12906-12914	distance	_
82-18	12915-12928	communication	_
82-19	12929-12932	and	_
82-20	12933-12937	more	_
82-21	12938-12946	reliance	_
82-22	12947-12949	on	_
82-23	12950-12958	multiple	_
82-24	12959-12966	smaller	_
82-25	12967-12968	“	_
82-26	12969-12974	jumps	_
82-27	12975-12976	”	_
82-28	12977-12984	between	_
82-29	12985-12992	regions	_
82-30	12993-12994	.	_

83-1	12995-12998	The	_
83-2	12999-13003	mean	_
83-3	13004-13014	clustering	_
83-4	13015-13026	coefficient	_
83-5	13027-13028	(	_
83-6	13029-13032	MCC	_
83-7	13033-13034	)	_
83-8	13035-13043	reflects	_
83-9	13044-13047	the	_
83-10	13048-13055	density	_
83-11	13056-13058	of	_
83-12	13059-13064	local	_
83-13	13065-13076	connections	_
83-14	13077-13078	.	_

84-1	13079-13085	Global	_
84-2	13086-13096	efficiency	_
84-3	13097-13098	(	_
84-4	13099-13103	GLOB	_
84-5	13104-13105	)	_
84-6	13106-13107	,	_
84-7	13108-13117	inversely	_
84-8	13118-13125	related	_
84-9	13126-13128	to	_
84-10	13129-13133	path	_
84-11	13134-13140	length	_
84-12	13141-13142	,	_
84-13	13143-13151	reflects	_
84-14	13152-13162	properties	_
84-15	13163-13165	of	_
84-16	13166-13169	the	_
84-17	13170-13177	network	_
84-18	13178-13188	associated	_
84-19	13189-13193	with	_
84-20	13194-13204	long-range	_
84-21	13205-13216	connections	_
84-22	13217-13221	that	_
84-23	13222-13232	facilitate	_
84-24	13233-13238	rapid	_
84-25	13239-13252	communication	_
84-26	13253-13260	between	_
84-27	13261-13267	remote	_
84-28	13268-13273	brain	_
84-29	13274-13281	regions	_
84-30	13282-13283	;	_
84-31	13284-13286	it	_
84-32	13287-13289	is	_
84-33	13290-13297	thought	_
84-34	13298-13300	to	_
84-35	13301-13308	reflect	_
84-36	13309-13312	the	_
84-37	13313-13320	network	_
84-38	13321-13323	's	_
84-39	13324-13332	capacity	_
84-40	13333-13336	for	_
84-41	13337-13345	parallel	_
84-42	13346-13357	information	_
84-43	13358-13369	propagation	_
84-44	13370-13373	and	_
84-45	13374-13384	processing	_
84-46	13385-13386	.	_

85-1	13387-13389	In	_
85-2	13390-13398	contrast	_
85-3	13399-13400	,	_
85-4	13401-13406	local	_
85-5	13407-13417	efficiency	_
85-6	13418-13419	(	_
85-7	13420-13423	LOC	_
85-8	13424-13425	)	_
85-9	13426-13428	is	_
85-10	13429-13436	thought	_
85-11	13437-13439	to	_
85-12	13440-13447	reflect	_
85-13	13448-13458	properties	_
85-14	13459-13461	of	_
85-15	13462-13465	the	_
85-16	13466-13473	network	_
85-17	13474-13484	associated	_
85-18	13485-13489	with	_
85-19	13490-13497	modular	_
85-20	13498-13508	processing	_
85-21	13509-13515	within	_
85-22	13516-13520	more	_
85-23	13521-13530	localized	_
85-24	13531-13536	brain	_
85-25	13537-13544	regions	_
85-26	13545-13546	.	_

86-1	13547-13549	In	_
86-2	13550-13557	network	_
86-3	13558-13563	graph	_
86-4	13564-13575	mathematics	_
86-5	13576-13577	,	_
86-6	13578-13582	cost	_
86-7	13583-13586	has	_
86-8	13587-13599	implications	_
86-9	13600-13603	for	_
86-10	13604-13611	overall	_
86-11	13612-13622	topography	_
86-12	13623-13625	of	_
86-13	13626-13629	the	_
86-14	13630-13637	network	_
86-15	13638-13641	and	_
86-16	13642-13647	there	_
86-17	13648-13651	are	_
86-18	13652-13660	multiple	_
86-19	13661-13666	costs	_
86-20	13667-13669	at	_
86-21	13670-13675	which	_
86-22	13676-13679	the	_
86-23	13680-13687	network	_
86-24	13688-13695	metrics	_
86-25	13696-13699	can	_
86-26	13700-13702	be	_
86-27	13703-13711	examined	_
86-28	13712-13713	.	_

87-1	13714-13716	We	_
87-2	13717-13725	examined	_
87-3	13726-13729	the	_
87-4	13730-13738	networks	_
87-5	13739-13741	at	_
87-6	13742-13743	a	_
87-7	13744-13748	cost	_
87-8	13749-13751	at	_
87-9	13752-13757	which	_
87-10	13758-13761	all	_
87-11	13762-13774	participants	_
87-12	13775-13778	had	_
87-13	13779-13794	fully-connected	_
87-14	13795-13803	networks	_
87-15	13804-13805	.	_

88-1	13806-13807	A	_
88-2	13808-13823	fully-connected	_
88-3	13824-13831	network	_
88-4	13832-13840	contains	_
88-5	13841-13843	at	_
88-6	13844-13849	least	_
88-7	13850-13853	one	_
88-8	13854-13862	possible	_
88-9	13863-13870	pathway	_
88-10	13871-13878	between	_
88-11	13879-13884	every	_
88-12	13885-13889	node	_
88-13	13890-13891	.	_

89-1	13892-13903	Statistical	_
89-2	13904-13912	Analyses	_
89-3	13913-13924	Demographic	_
89-4	13925-13929	data	_
89-5	13930-13934	were	_
89-6	13935-13941	tested	_
89-7	13942-13945	for	_
89-8	13946-13951	group	_
89-9	13952-13963	differences	_
89-10	13964-13969	using	_
89-11	13970-13989	independent-samples	_
89-12	13990-13997	t-tests	_
89-13	13998-14001	and	_
89-14	14002-14012	chi-square	_
89-15	14013-14021	analyses	_
89-16	14022-14023	.	_

90-1	14024-14031	T-tests	_
90-2	14032-14035	and	_
90-3	14036-14046	chi-square	_
90-4	14047-14055	analyses	_
90-5	14056-14062	tested	_
90-6	14063-14066	for	_
90-7	14067-14078	differences	_
90-8	14079-14086	between	_
90-9	14087-14099	participants	_
90-10	14100-14103	who	_
90-11	14104-14108	were	_
90-12	14109-14117	included	_
90-13	14118-14120	in	_
90-14	14121-14124	the	_
90-15	14125-14130	study	_
90-16	14131-14133	vs	_
90-17	14134-14139	those	_
90-18	14140-14143	who	_
90-19	14144-14148	were	_
90-20	14149-14157	excluded	_
90-21	14158-14159	.	_

91-1	14160-14167	T-tests	_
91-2	14168-14172	were	_
91-3	14173-14177	used	_
91-4	14178-14180	to	_
91-5	14181-14185	test	_
91-6	14186-14189	for	_
91-7	14190-14201	differences	_
91-8	14202-14204	in	_
91-9	14205-14211	motion	_
91-10	14212-14222	parameters	_
91-11	14223-14230	between	_
91-12	14231-14234	the	_
91-13	14235-14238	PAE	_
91-14	14239-14244	group	_
91-15	14245-14248	and	_
91-16	14249-14257	controls	_
91-17	14258-14259	.	_

92-1	14260-14265	Prior	_
92-2	14266-14268	to	_
92-3	14269-14272	the	_
92-4	14273-14280	primary	_
92-5	14281-14289	analyses	_
92-6	14290-14291	,	_
92-7	14292-14293	a	_
92-8	14294-14300	number	_
92-9	14301-14303	of	_
92-10	14304-14313	potential	_
92-11	14314-14325	confounding	_
92-12	14326-14333	factors	_
92-13	14334-14338	were	_
92-14	14339-14347	examined	_
92-15	14348-14350	by	_
92-16	14351-14358	testing	_
92-17	14359-14362	for	_
92-18	14363-14368	group	_
92-19	14369-14380	differences	_
92-20	14381-14386	using	_
92-21	14387-14392	ANVOA	_
92-22	14393-14394	.	_

93-1	14395-14397	If	_
93-2	14398-14400	no	_
93-3	14401-14412	significant	_
93-4	14413-14418	group	_
93-5	14419-14430	differences	_
93-6	14431-14435	were	_
93-7	14436-14441	found	_
93-8	14442-14448	across	_
93-9	14449-14455	levels	_
93-10	14456-14458	of	_
93-11	14459-14462	the	_
93-12	14463-14474	potentially	_
93-13	14475-14486	confounding	_
93-14	14487-14495	variable	_
93-15	14496-14497	,	_
93-16	14498-14501	the	_
93-17	14502-14510	variable	_
93-18	14511-14514	was	_
93-19	14515-14518	not	_
93-20	14519-14529	controlled	_
93-21	14530-14533	for	_
93-22	14534-14536	in	_
93-23	14537-14547	subsequent	_
93-24	14548-14556	analyses	_
93-25	14557-14558	.	_

94-1	14559-14566	Primary	_
94-2	14567-14575	analyses	_
94-3	14576-14585	comparing	_
94-4	14586-14592	groups	_
94-5	14593-14594	(	_
94-6	14595-14598	PAE	_
94-7	14599-14602	vs.	_
94-8	14603-14610	control	_
94-9	14611-14612	)	_
94-10	14613-14615	on	_
94-11	14616-14623	network	_
94-12	14624-14636	connectivity	_
94-13	14637-14645	measures	_
94-14	14646-14655	consisted	_
94-15	14656-14658	of	_
94-16	14659-14670	independent	_
94-17	14671-14678	samples	_
94-18	14679-14686	t-tests	_
94-19	14687-14688	.	_

95-1	14689-14692	The	_
95-2	14693-14699	impact	_
95-3	14700-14702	of	_
95-4	14703-14711	multiple	_
95-5	14712-14723	comparisons	_
95-6	14724-14727	was	_
95-7	14728-14737	addressed	_
95-8	14738-14742	with	_
95-9	14743-14752	Benjamini	_
95-10	14753-14756	and	_
95-11	14757-14765	Hochberg	_
95-12	14766-14771	False	_
95-13	14772-14781	Discovery	_
95-14	14782-14786	Rate	_
95-15	14787-14788	(	_
95-16	14789-14792	FDR	_
95-17	14793-14794	)	_
95-18	14795-14805	correction	_
95-19	14806-14807	.	_

96-1	14808-14809	A	_
96-2	14810-14818	multiple	_
96-3	14819-14824	ANOVA	_
96-4	14825-14828	was	_
96-5	14829-14837	utilized	_
96-6	14838-14840	to	_
96-7	14841-14845	test	_
96-8	14846-14849	for	_
96-9	14850-14855	group	_
96-10	14856-14867	differences	_
96-11	14868-14869	(	_
96-12	14870-14873	PAE	_
96-13	14874-14877	vs.	_
96-14	14878-14885	control	_
96-15	14886-14887	)	_
96-16	14888-14890	in	_
96-17	14891-14905	neurocognitive	_
96-18	14906-14917	functioning	_
96-19	14918-14919	.	_

97-1	14920-14926	Lastly	_
97-2	14927-14928	,	_
97-3	14929-14936	Pearson	_
97-4	14937-14949	correlations	_
97-5	14950-14954	were	_
97-6	14955-14959	used	_
97-7	14960-14962	to	_
97-8	14963-14971	directly	_
97-9	14972-14979	examine	_
97-10	14980-14993	relationships	_
97-11	14994-15001	between	_
97-12	15002-15009	network	_
97-13	15010-15022	connectivity	_
97-14	15023-15030	metrics	_
97-15	15031-15034	and	_
97-16	15035-15046	performance	_
97-17	15047-15049	on	_
97-18	15050-15064	neurocognitive	_
97-19	15065-15070	tests	_
97-20	15071-15072	.	_

